glp-1 and dual glp-1/gip receptor agonists Fair Allocation of GLP-1–GIP Science Behind GLP 1 GIP

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Given the relatively smaller reduction in body weight (9.4%) in the SELECT trial compared to previous RCTs: 14.9% in STEP1 (BMI 37.86.7 kg/m 2 ) [16] and 13.2% STEP6 (BMI 31.9 kg/m 2 ) [49], pleiotropic effects of semaglutide may contribute to the overall CV risk reduction [25,37]

Getting your prescription approved involves jumping through specific hoops

This approach is proving effective at delivering both cardiovascular and kidney benefits, offering a powerful strategy for improving patient outcomes

An analysis of CDC data also found that Black and Hispanic adults in the U.S